Takayasu arteritis (TA) is a true orphan disease. There are no published controlled clinical trials and the evidence on which to develop management strategies and therapeutic guidelines is rudimentary, particularly when compared to the advances seen in other vasculitides and inflammatory rheumatic diseases. Additional significant challenges to more effective management exist. These include a lack of awareness of the disease and a resultant delay in diagnosis, as well as the absence of gold standards for the quantification of disease activity and imaging. However, the outlook is beginning to change for the better, with early evidence pointing towards improved outcomes for patients. This improvement reflects earlier use of combined immunosuppression and the increased availability of noninvasive imaging modalities, particularly 18F-fluorodeoxyglucose positron emission computerized tomography (18F-FDG-CT-PET), high-resolution ultrasound (US), magnetic resonance, and CT angiography (MRA and CTA).

Perhaps in light of the paucity of clinical trial evidence, corticosteroids remain the mainstay of therapy and achieve remission in 60% of cases. However, when tapered, most patients relapse. Our practice is to initiate combination immunosuppressive therapy at diagnosis to optimize control of disease activity and steroid-sparing. Small open-label studies support the efficacy of methotrexate, azathioprine, and mycophenolate. Although cyclophosphamide is typically reserved for refractory or life-threatening disease, we have some concerns about its efficacy in TA, and its use is often contraindicated due to a need to preserve fertility in this young, predominantly female, patient group. Despite optimal combination immunosuppression, up to 30% of patients fail to respond adequately.

This observation led to the investigation of biologic therapies already available for other rheumatic diseases. Nearly a decade ago Hoffman and colleagues reported the initial open-label study demonstrating the efficacy of tumor necrosis factor-α (TNF-α) blockade in TA. Since then, these findings have been further validated in the most refractory of patients. Akin to the experience in rheumatoid arthritis (RA), a proportion of patients with TA failed to respond to TNF-α antagonists, leading to the search for alternative therapeutic targets.

The biological actions of interleukin 6 (IL-6), alongside increased serum levels and its presence in the inflamed arterial wall in TA, suggest it plays a key pathogenic role. The TA inflammatory infiltrate comprises activated dendritic cells, α/β and γδ T lymphocytes, B lymphocytes, macrophages, and multinucleate giant cells. This inflammatory insult predisposes to intimal myofibroblast proliferation and fibrosis, with stenosis or occlusion of the arterial lumen. IL-6 is a pleiotropic cytokine, which may influence the function of many of these cell types. For example, IL-6 is important for T and B lymphocyte differentiation, generation of fibroblast proliferation, and for driving hepatocyte synthesis of acute phase proteins, including C-reactive protein (CRP). Fortuitously, the humanized anti-IL-6 receptor monoclonal antibody tocilizumab and the anti-CD20 monoclonal antibody rituximab have been extensively studied in RA, and a preliminary report of 3 patients with TA treated with rituximab suggests B-cell depletion may be effective, although further confirmatory studies are required. The first report of IL-6R blockade in TA described a dramatic prolonged response, with reduction in aortic wall thickness and resolution of ischemic symptoms, suggesting a disease-modifying effect. Subsequently, small case series have described the further use of tocilizumab, with 44 patients included in a metaanalysis. At time of analysis, just over half these patients continued taking tocilizumab therapy. Among the remainder, one-third achieved disease remission, and tocilizumab was stopped. In 40% of cases, treatment was withdrawn in the face of persistent radiological progression or disease relapse, while 20% suffered intolerable side effects.

In this issue of *The Journal*, Tombetti and colleagues have described the further use of tocilizumab, with 44 patients included in a metaanalysis. At time of analysis, just over half these patients continued taking tocilizumab therapy. Among the remainder, one-third achieved disease remission, and tocilizumab was stopped. In 40% of cases, treatment was withdrawn in the face of persistent radiological progression or disease relapse, while 20% suffered intolerable side effects.

See Treatment of refractory TA with tocilizumab, page 2047
report their retrospective review of 62 patients with TA seen in their center between 2004 and 2012. Of these, 29 (47%) received biologic therapy for refractory disease, defined as failure to achieve a prednisone dose of ≤ 7.5 mg/day, despite receiving at least 1 additional immunosuppressive drug. The percentage of patients requiring biologics is very high, with 22 patients receiving TNF-α antagonists and 7 receiving tocilizumab. This is the largest single series of patients treated with IL-6R blockade reported in detail.

The aim of the study was to evaluate the safety and efficacy of tocilizumab therapy in TA. Using a novel high resolution imaging approach the authors report that a proportion of patients responded well. However, their data also tells a cautionary tale, emphasizing the need for further realistic and thorough assessment of the benefits and limitations of IL-6R blockade in large vessel vasculitis. Although the study is small, retrospective, and lacks a control group, it raises important clinical issues. Critically, the authors stress that synthesis of acute phase proteins, such as CRP, serum amyloid A, and fibrinogen, will be suppressed in all patients receiving adequate doses of tocilizumab, and that the erythrocyte sedimentation rate (ESR) will also fall. Additionally, fever, malaise, and lethargy will resolve, while anemia, hypoalbuminemia, and thrombocytosis are typically reversed (Figure 1). This is true for all 7 patients in the current study, for the 44 included in the metanalysis, and in our clinical experience. Thus, symptoms and biomarkers, such as CRP and ESR, cannot be relied upon as an estimate of disease activity, and decisions to change treatment should not be based on them. This includes dose reduction of immunosuppressants, which should be used in combination with tocilizumab, as in the current study. Further, the accuracy of disease activity indices, such as the US National Institutes of Health (NIH) criteria and Indian Takayasu Clinical Activity Score (ITAS) 2010, which incorporate ESR and/or CRP, may be compromised, a fact recognized by the authors.

Although the response to IL-6R blockade supports a role for IL-6 in TA pathogenesis, the study findings also confirm that tocilizumab-induced suppression of symptoms and the acute phase response does not equate to complete inhibition of arterial wall inflammation and disease remission. This is further highlighted by reports of 3 other patients in whom tocilizumab therapy led to the rapid resolution of symptoms and the acute phase response, while disease in the arterial wall progressed, as evidenced by detection of new or progressive arterial injury using CTA and MRA. Unfortunately, 18F-FDG-CT-PET data are not available for the 7 patients included in the latest study. Of note, 18F-FDG-CT-PET scans performed pre- and post introduction of tocilizumab seem to reveal complete suppression of FDG uptake. Although these findings support a role for IL-6 in the increased FDG uptake, they also imply that 18F-FDG-CT-PET may be insensitive for detection of relapsing disease in those receiving tocilizumab. Nonetheless, 18F-FDG-CT-PET is not widely used during...
Moreover, our understanding of IL-6 actions in the arterial wall is limited. Further consideration must be given to the suggestion that IL-6 may have a protective homeostatic role in the arterial wall. In giant cell arteritis, elevated IL-6 levels correlated with a reduced incidence of ischemic complications\(^{19}\). Thus, inhibition in some settings may predispose to arterial injury.

Inflammation and arterial injury in TA is a complex multifactorial process. Inhibition of IL-6 signaling may provide another therapeutic tool for some patients with refractory TA, with detailed noninvasive imaging mandatory during followup, due to the complete suppression of the acute phase response. The importance of high-resolution US and MRA for the detection of subclinical progressive disease in those receiving tocilizumab is shown in the current study. Further advances may allow us to discern the nature of these lesions and distinguish inflammatory change from arterial remodelling or chronic fibrotic disease. The development of novel PET ligands may be useful in this regard\(^{20}\). Combination imaging data of this type would allow stratified therapy, with optimized regimens developed and selected specifically for inflammatory lesions. In contrast, myofibroblast proliferation might be targeted more appropriately using drugs with an anti-proliferative action, such as sirolimus and everolimus. Nonetheless, the perennial challenge in this orphan disease remains, namely, the need to initiate prospective, multinational controlled clinical trials, with defined end-points incorporating novel disease activity indices, such as ITAS2010 and noninvasive image scores.

**TARYN YOUNGSTEIN**, BS, MRCP, Specialist Registrar in Rheumatology; **JUSTIN C. MASON**, PhD, FRCP, Professor of Vascular Rheumatology, Rheumatology Section and Vascular Sciences, Faculty of Medicine, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK

Supported in part by the Imperial College London National Institute for Health Research Biomedical Research Centre funding scheme.

Address correspondence to Professor Mason; Vascular Sciences, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK. E-mail: justin.mason@imperial.ac.uk

**REFERENCES**


5. Liang P, Hoffman GS. Advances in the medical and surgical...


